BTIG analyst Mark Massaro raised the firm’s price target on Bionano Genomics to $10 from $2 and keeps a Buy rating on the shares. The analyst cites the company’s better than expected Q2 revenue and affirmed FY23 revenue guidance. The key takeaway from the Q2 earnings call was that Bionano drove tremendous 108% growth in flowcells, which underpins the strong demand for the company’s platform, the firm tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BNGO:
- Bionano Announces Presentation of Optical Genome Mapping (OGM) Utility Across Cancer Research Applications at the Cancer Genomics Consortium (CGC) 2023 Annual Meeting
- Bionano Genomics reports Q2 revenue $8.7M, consensus $8.29M
- Bionano Reports Second Quarter 2023 Results and Highlights Recent Business Progress
- Bionano Genomics options imply 13.1% move in share price post-earnings
- Bionano Genomics Announces Reverse Stock Split